Delaware
|
84-1475642
|
|
(State
or other jurisdiction of
|
1180
Avenue of the Americas, 19th
Floor
|
(I.R.S.
Employer
|
Incorporation
or organization)
|
New
York, New York 10036
Telephone
(646) 214-0700
|
Identification
No.)
|
Title
of
Securities
to be Registered
|
Proposed
Maximum Amount to be
Registered
|
Proposed
Maximum
Offering
Price
Per
Share (1)
|
Aggregate
Offering
Price (1)
|
Amount
of
Registration
Fee
|
Common
Stock, par value $.001 per share
|
750,000
|
$5.565
|
$4,173,750
|
$446.59
|
(1)
|
Estimated
solely for the purpose of determining the registration fee pursuant
to
Rule 457(c) and (h) and based upon the average low and high sales
prices
of the Registrant’s Common Stock on May 16, 2006, as reported on the OTC
bulletin board.
|
(a)
|
Annual
Report on Form 10-KSB for the fiscal year ended December 31, 2005
filed on
March 20, 2006, as amended by Form 10-KSB/A filed on April 12,
2006;
|
(a)
|
Quarterly
Report on Form 10-QSB for the fiscal quarter ended March 31, 2006
filed on
May 15, 2006;
|
(b)
|
Current
Reports on Form 8-K filed on April 26, 2006 and May 3, 2006;
and
|
(c)
|
Registration
Statement on Form SB-2 filed November 14, 2005 (SEC File No. 333-129680),
as amended by Post-effective Amendment No. 1 to Form SB-2 filed April
3,
2006, containing the description of capital stock as set forth in
the
section entitled “Description of Capital Stock,” as such description is
amended in the section entitled “Description of Capital Stock” in
Prospectus Supplement No. 1 filed April 26, 2006pursuant to Rule
424(b)
promulgated under the Securities Act of 1933, as
amended.
|
Exhibit
|
Description
|
|
4.1
|
ZIOPHARM
Oncology, Inc. 2003 Stock Option Plan (incorporated by reference
to
Exhibit 10.1 to the Registrant’s Registration Statement on Form SB-2, SEC
File No. 333-129020, filed on October 14, 2005)
|
|
4.2
|
Amendment
No. 1 to ZIOPHARM Oncology, Inc. 2003 Stock Option Plan (incorporated
by
reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K
filed on April 26, 2006)
|
|
5.1
|
Opinion
of Maslon Edelman Borman & Brand, LLP as to the legality of the
securities being registered
|
|
23.1
|
Consent
of Independent Registered Public Accounting Firm - Vitale, Caturano
&
Company, Ltd.
|
|
23.3
|
Consent
of Maslon Edelman Borman & Brand, LLP (included in Exhibit
5.1)
|
|
24.1
|
Power
of Attorney (included on signature page
hereof)
|
(a)
|
The
Registrant hereby undertakes:
|
ZIOPHARM Oncology, Inc. | ||
|
|
|
By: | /s/ Jonathan Lewis | |
Jonathan
Lewis
Chief
Executive Officer
|
||
Name
|
Title
|
Date
|
|
/s/
Jonathan Lewis
|
Director
and Chief Executive Officer
|
May
19, 2006
|
|
Jonathan
Lewis
|
(Principal
Executive Officer)
|
||
/s/
Richard Bagley
|
Director,
President, Treasurer and Chief Operating Officer
|
May
19, 2006
|
|
Richard
Bagley
|
(Principal
Accounting and Financial Officer)
|
||
|
Director
|
May
19, 2006
|
|
Murray
Brennan
|
|||
/s/
James Cannon
|
Director
|
May
19, 2006
|
|
James
Cannon
|
|||
/s/
Timothy McInerney
|
Director
|
May
19, 2006
|
|
Timothy
McInerney
|
|||
/s/
Wyche Fowler, Jr.
|
Director
|
May
19, 2006
|
|
Wyche
Fowler, Jr.
|
|||
/s/
Gary S. Fragin
|
Director
|
May
19, 2006
|
|
Gary
S. Fragin
|
|||
/s/
Michael Weiser
|
Director
|
May
19, 2006
|
|
Michael
Weiser
|
Exhibit
|
Description
|
|
5.1
|
Opinion
of Maslon Edelman Borman & Brand, LLP as to the legality of the
securities being registered
|
|
23.1
|
Consent
of Independent Registered Public Accounting Firm - Vitale, Caturano
&
Company, Ltd.
|